

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 07/11/2017

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GIUE	data CTS	AIC	Confezione
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678012	1
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678024	2
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678036	3
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678048	4
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678051	5
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678063	6
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678075	7
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678087	8
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678099	9
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678101	10
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678113	11
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678125	12
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678137	13
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678149	14
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678152	15
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678164	16
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678176	17
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678188	18
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678190	19
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678202	20
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678214	21
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678226	22
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678238	23
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678240	24
Lacosamide Accord	EMEA/H/C/4443	N03AX18	lacosamide	Accord Healthcare Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045678253	25
Rydapt	EMEA/H/C/4095	L01XE39	Midostaurina	Novartis Europharm Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045612013	1
Bavencio	EMEA/H/C/4338	Pending	avelumab	Merck Serono Europe Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	045613015	1
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672019	1
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672021	2
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672033	3
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672045	4
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672058	5
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672060	6
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672072	7
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672084	8
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672096	9
Entecavir Mylan	EMEA/H/C/4377	J05AF10	entecavir	Mylan S.A.S.	20-lug-17	18-set-17	27-ott-17	08-nov-17	045672108	10
Xermelo	EMEA/H/C/3937	Pending	telotristat	Ipsen Pharma	20-lug-17	18-set-17	27-ott-17	08-nov-17	045682010	1
Xermelo	EMEA/H/C/3937	Pending	telotristat	Ipsen Pharma	20-lug-17	18-set-17	27-ott-17	08-nov-17	045682022	2
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan	EMEA/H/C/4240	J05AR06	Efavirenz / emtricitabina / tenofovir disoproxil	Mylan S.A.S.	22-giu-17	05-set-17	27-ott-17	08-nov-17	045670015	1
Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan	EMEA/H/C/4240	J05AR06	Efavirenz / emtricitabina / tenofovir disoproxil	Mylan S.A.S.	22-giu-17	05-set-17	27-ott-17	08-nov-17	045670027	2
Cuprior	EMEA/H/C/4005	A16AX12	trientina	gmp-orphan SA	21-apr-17	05-set-17	27-ott-17	08-nov-17	045679014	1
Symtuza	EMEA/H/C/4391/00	Pending	darunavir / cobicistat / emtricitabina / tenofovir alafenamide	Janssen-Cilag International NV	20-lug-17	21-set-17	27-ott-17	08-nov-17	045660014	1
Tecentriq	EMEA/H/C/4143	Pending	atezolizumab	Roche Registration Limited	20-lug-17	21-set-17	27-ott-17	08-nov-17	045590015	1
Lartruvo	EMEA/H/C/4216/1B/03/G	L01XC27	olaratumab	Eli Lilly Nederland B.V.	07-apr-17	21-set-17	27-ott-17	08-nov-17	045174024	2
Lartruvo	EMEA/H/C/4216/1B/03/G	L01XC27	olaratumab	Eli Lilly Nederland B.V.	07-apr-17	21-set-17	27-ott-17	08-nov-17	045174036	3
Zebinix	EMEA/H/C/988/1B/0063/G	N03AF04	Eslicarbazepina acetato	Bial - Portela e Cª, SA	18-lug-17	18-set-17	27-ott-17	08-nov-17	039910258	25
Zebinix	EMEA/H/C/988/1B/0063/G	N03AF04	Eslicarbazepina acetato	Bial - Portela e Cª, SA	18-lug-17	18-set-17	27-ott-17	08-nov-17	039910260	26
Samsca	EMEA/H/C/980/X/24	C03XA01	tolvaptan	Otsuka Pharmaceutical Europe Ltd.	20-lug-17	18-set-17	27-ott-17	08-nov-17	039551054	5

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 07/11/2017

Samsca	EMA/H/C/980/X/24	C03XA01	tolvaptan	Otsuka Pharmaceutical Europe Ltd.	20-lug-17	18-set-17	27-ott-17	08-nov-17	039551066	6
Signifor		H01CB05	pasireotide	Novartis Europharm Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	042032185	18
Signifor		H01CB05	pasireotide	Novartis Europharm Limited	20-lug-17	18-set-17	27-ott-17	08-nov-17	042032197	19
Wakix	EMA/H/C/2616/IB/08	N07XX11	pitolisant cloridrato	Bioprojet Pharma	20-lug-17	14-set-17	27-ott-17	08-nov-17	044839037	3
Olazax Disperzi	EMA/H/C/1088/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	14-set-17	27-ott-17	08-nov-17	045680067	6
Olazax Disperzi	EMA/H/C/1088/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	14-set-17	27-ott-17	08-nov-17	045680079	7
Olazax Disperzi	EMA/H/C/1088/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	14-set-17	27-ott-17	08-nov-17	045680081	8
Olazax Disperzi	EMA/H/C/1088/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	14-set-17	27-ott-17	08-nov-17	045680093	9
Olazax Disperzi	EMA/H/C/1088/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	14-set-17	27-ott-17	08-nov-17	045680105	10
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919243	24
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919256	25
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919268	26
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919270	27
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919282	28
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919294	29
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919306	30
Vimpat	EMA/H/C/000863/IAIN/0067/G	N03AX18	lacosamide	UCB Pharma S.A.		14-set-17	27-ott-17	08-nov-17	038919318	31
Ventavis	EMA/H/C/474/II/51/G	B01AC11	Iloprost	Bayer Pharma AG	13-ott-16	11-set-17	27-ott-17	08-nov-17	036019139	13
Ventavis	EMA/H/C/474/II/51/G	B01AC11	Iloprost	Bayer Pharma AG	13-ott-16	11-set-17	27-ott-17	08-nov-17	036019141	14
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889083	8
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889095	9
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889107	10
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889119	11
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889121	12
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889133	13
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889145	14
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889158	15
Neparvis		C09DX04	sacubitril / valsartan	Novartis Europharm Limited	21-set-16	11-set-17	27-ott-17	08-nov-17	044889160	16
Olazax	EMA/H/C/1087/IB/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	05-set-17	27-ott-17	08-nov-17	045681069	6
Olazax	EMA/H/C/1087/IB/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	05-set-17	27-ott-17	08-nov-17	045681071	7
Olazax	EMA/H/C/1087/IB/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	05-set-17	27-ott-17	08-nov-17	045681083	8
Olazax	EMA/H/C/1087/IB/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	05-set-17	27-ott-17	08-nov-17	045681095	9
Olazax	EMA/H/C/1087/IB/WS/1098/G	N05AH03	Olanzapina	Glenmark Pharmaceuticals s.r.o.	09-feb-17	05-set-17	27-ott-17	08-nov-17	045681107	10
Lutathera	EMA/H/C/004123	V10XX04	lutetio (177Lu) oxodotreotide	Advanced Accelerator Applications	20-lug-17	26-set-17	27-ott-17	08-nov-17	045677010	1
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676018	1
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676020	2
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676032	3
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676044	4
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676057	5
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676069	6
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676071	7
Dupixent	EMA/H/C/004390	Pending	dupilumab	Sanofi-Aventis groupe	20-lug-17	26-set-17	27-ott-17	08-nov-17	045676083	8
Stayveer	EMA/H/C/2644/IB/15	C02KX01	bosentan	Marklas Nederland B.V.	15-set-17	26-set-17	27-ott-17	08-nov-17	042926055	5
Stayveer	EMA/H/C/2644/IB/15	C02KX01	bosentan	Marklas Nederland B.V.	15-set-17	26-set-17	27-ott-17	08-nov-17	042926067	6
Entecavir Accord	EMA/H/C/004458	J05AF10	entecavir	Accord Healthcare Limited	20-lug-17	26-set-17	27-ott-17	08-nov-17	045675016	1
Entecavir Accord	EMA/H/C/004458	J05AF10	entecavir	Accord Healthcare Limited	20-lug-17	26-set-17	27-ott-17	08-nov-17	045675028	2

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 07/11/2017

Entecavir Accord	EMA/H/C/004458	J05AF10	entecavir	Accord Healthcare Limited	20-lug-17	26-set-17	27-ott-17	08-nov-17	045675030	3
Entecavir Accord	EMA/H/C/004458	J05AF10	entecavir	Accord Healthcare Limited	20-lug-17	26-set-17	27-ott-17	08-nov-17	045675042	4
Entecavir Accord	EMA/H/C/004458	J05AF10	entecavir	Accord Healthcare Limited	20-lug-17	26-set-17	27-ott-17	08-nov-17	045675055	5
Entecavir Accord	EMA/H/C/004458	J05AF10	entecavir	Accord Healthcare Limited	20-lug-17	26-set-17	27-ott-17	08-nov-17	045675067	6
Xtandi	EMA/H/C/2639/X/29	L02BB04	enzalutamide	Astellas Pharma Europe B.V.	20-lug-17	21-set-17	27-ott-17	08-nov-17	042868024	2
Xtandi	EMA/H/C/2639/X/29	L02BB04	enzalutamide	Astellas Pharma Europe B.V.	20-lug-17	21-set-17	27-ott-17	08-nov-17	042868036	3
neupro	EMA/H/C/000626/IAIN/0076 EMA/H/C/000626/IAIN/0078	N04BC09	Rotigotine	UCB Pharma S.A.	01-giu-17	28-set-17	27-ott-17	08-nov-17	037152307	56
neupro	EMA/H/C/000626/IAIN/0076 EMA/H/C/000626/IAIN/0078	N04BC09	Rotigotine	UCB Pharma S.A.	01-giu-17	28-set-17	27-ott-17	08-nov-17	037152319	57
neupro	EMA/H/C/000626/IAIN/0076 EMA/H/C/000626/IAIN/0078	N04BC09	Rotigotine	UCB Pharma S.A.	01-giu-17	28-set-17	27-ott-17	08-nov-17	037152321	58
neupro	EMA/H/C/000626/IAIN/0076 EMA/H/C/000626/IAIN/0078	N04BC09	Rotigotine	UCB Pharma S.A.	01-giu-17	28-set-17	27-ott-17	08-nov-17	037152333	59
neupro	EMA/H/C/000626/IAIN/0076 EMA/H/C/000626/IAIN/0078	N04BC09	Rotigotine	UCB Pharma S.A.	01-giu-17	28-set-17	27-ott-17	08-nov-17	037152345	60
neupro	EMA/H/C/000626/IAIN/0076 EMA/H/C/000626/IAIN/0078	N04BC09	Rotigotine	UCB Pharma S.A.	01-giu-17	28-set-17	27-ott-17	08-nov-17	037152358	61
Alecensa	EMA/H/C/4164/1B/0008/G	L01XE36	alectinib	Roche Registration Limited	25-set-17	-	-	08-nov-17	045267022	2

La responsabilità di qualsiasi onere e/o attività che l' Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all' immissione in commercio del medicinale, è totalmente a carico dell' Azienda stessa. L' ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.